Hemostemix Inc. announced it will present at the Centurion One Capital 4th Annual Bahamas Summit in October 2026, highlighting its VesCell™ stem cell therapy. The company plans to discuss VesCell's commercialization in The Bahamas, supported by extensive clinical evidence including 498 treatments and seven studies. Hemostemix has applied for a commercial Phase I clinical trial under The Bahamas' Longevity and Regenerative Therapies Act to treat angina, vascular dementia, and pain. This event offers Hemostemix a platform to connect investors with clinical partners and patient outcomes, advancing its innovative regenerative therapy.
Hemostemix's upcoming presentation at the Centurion One Capital Bahamas Summit provides context for readers following health innovations. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 29, 2026 00:51 WIB: Out of 100 priced US health-sector stocks tradable on Pluang, 53 rose and 44 fell. Notable movers include ACADIA Pharmaceuticals Inc. (ACAD) at USD 19.98 with a 1-day change of -3.38% and a typical hold time of 76 days, Adaptive Biotechnologies Corp (ADPT) at USD 28.48 down 3.23% with a 36-day hold, and GeneDx Holdings Corp (WGS) at USD 85.66 down 3.10% with a 19-day hold.
Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...
H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...
Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...
Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...
Bittensor has introduced a proposal for Gamma tokens, a new economic layer allowing its subnets to trade compute and inference services using credits backed by their own TAO emissions. This shifts TAO from being solely a reward token to also serving ...
